Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
4 recherche sur le mot-clé 'aripiprazole'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Aripiprazole in patients with autistic spectrum disorders: a review and case reports / Eiji KIRINO in Autism - Open Access, 2-S ([01/12/2012])
[article]
Titre : Aripiprazole in patients with autistic spectrum disorders: a review and case reports Type de document : Texte imprimé et/ou numérique Auteurs : Eiji KIRINO, Auteur Article en page(s) : 10 p. Langues : Anglais (eng) Mots-clés : Aripiprazole Autistic spectrum disorder Pervasive developmental disorders Asperger’s disorder Index. décimale : PER Périodiques Résumé : Background: Although a significant amount of literature regarding use of aripiprazole (APZ) in autistic spectrum disorders (ASDs) has benne published, APZ is not approved for use in autism or ASDs in countries other than the United States. Even in the United States, approved use of APZ is limited to the patients with autism in children and adolescents. This review and case reports focus on the available evidence and clinical experience regarding the use of APZ in patients with ASDs including adults Methods: A literature review was conducted, using the PubMed search term ‘aripiprazole’ and(‘autistic spectrum disorder’, ‘pervasive developmental disorders’ or ‘Asperger’s disorder’).Results: In previous reports, APZ can target symptoms such as anxiety, depression, aggression, and irritability. Compared with other antipsychotics, APZ also causes fewer adverse events that can lead to drug discontinuation. The case reports supported the literature review: APZ has moderate sedative, antidepressant, and antianxiety effects, when used to treat ASDs. None of the patients experienced adverse reactions (e.g., extrapyramidal symptoms, weight gain, and sedation).Conclusion: APZ reduces aggression in ASDs and improves qualitative deficits in interpersonal interactions and motivation. APZ also causes fewer adverse events. APZ may be associated with favorable treatment compliance, and may improve treatment of ASDs. En ligne : https://dx.doi.org/10.4172/2165-7890.S1-004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=409
in Autism - Open Access > 2-S [01/12/2012] . - 10 p.[article] Aripiprazole in patients with autistic spectrum disorders: a review and case reports [Texte imprimé et/ou numérique] / Eiji KIRINO, Auteur . - 10 p.
Langues : Anglais (eng)
in Autism - Open Access > 2-S [01/12/2012] . - 10 p.
Mots-clés : Aripiprazole Autistic spectrum disorder Pervasive developmental disorders Asperger’s disorder Index. décimale : PER Périodiques Résumé : Background: Although a significant amount of literature regarding use of aripiprazole (APZ) in autistic spectrum disorders (ASDs) has benne published, APZ is not approved for use in autism or ASDs in countries other than the United States. Even in the United States, approved use of APZ is limited to the patients with autism in children and adolescents. This review and case reports focus on the available evidence and clinical experience regarding the use of APZ in patients with ASDs including adults Methods: A literature review was conducted, using the PubMed search term ‘aripiprazole’ and(‘autistic spectrum disorder’, ‘pervasive developmental disorders’ or ‘Asperger’s disorder’).Results: In previous reports, APZ can target symptoms such as anxiety, depression, aggression, and irritability. Compared with other antipsychotics, APZ also causes fewer adverse events that can lead to drug discontinuation. The case reports supported the literature review: APZ has moderate sedative, antidepressant, and antianxiety effects, when used to treat ASDs. None of the patients experienced adverse reactions (e.g., extrapyramidal symptoms, weight gain, and sedation).Conclusion: APZ reduces aggression in ASDs and improves qualitative deficits in interpersonal interactions and motivation. APZ also causes fewer adverse events. APZ may be associated with favorable treatment compliance, and may improve treatment of ASDs. En ligne : https://dx.doi.org/10.4172/2165-7890.S1-004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=409 Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders / R. HOUGHTON in Autism Research, 14-8 (August 2021)
[article]
Titre : Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; J. VAN DEN BERGH, Auteur ; K. LAW, Auteur ; Y. LIU, Auteur ; F. DE VRIES, Auteur Article en page(s) : p.1800-1814 Langues : Anglais (eng) Mots-clés : Adolescent Antipsychotic Agents/adverse effects Aripiprazole/adverse effects Autism Spectrum Disorder/complications/drug therapy/epidemiology Child Cohort Studies Female Fractures, Bone/drug therapy/epidemiology Humans Male Retrospective Studies Risperidone/adverse effects United States/epidemiology antipsychotics aripiprazole autism spectrum disorder fractures risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18?years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10?years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449
in Autism Research > 14-8 (August 2021) . - p.1800-1814[article] Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; J. VAN DEN BERGH, Auteur ; K. LAW, Auteur ; Y. LIU, Auteur ; F. DE VRIES, Auteur . - p.1800-1814.
Langues : Anglais (eng)
in Autism Research > 14-8 (August 2021) . - p.1800-1814
Mots-clés : Adolescent Antipsychotic Agents/adverse effects Aripiprazole/adverse effects Autism Spectrum Disorder/complications/drug therapy/epidemiology Child Cohort Studies Female Fractures, Bone/drug therapy/epidemiology Humans Male Retrospective Studies Risperidone/adverse effects United States/epidemiology antipsychotics aripiprazole autism spectrum disorder fractures risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18?years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10?years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449 Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders / Selma TURAL HESAPCIOGLU in Research in Autism Spectrum Disorders, 72 (April 2020)
[article]
Titre : Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders Type de document : Texte imprimé et/ou numérique Auteurs : Selma TURAL HESAPCIOGLU, Auteur ; Mehmet Fatih CEYLAN, Auteur ; Meryem KASAK, Auteur ; Cansu P?nar SEN, Auteur Article en page(s) : p.101520 Langues : Anglais (eng) Mots-clés : Antipsychotic Aripiprazole Autism Spectrum Disorders Irritability Olanzapine Risperidone Index. décimale : PER Périodiques Résumé : Background The aim of this study is to examine the use of olanzapine, risperidone and aripiprazole in autism spectrum disorders (ASD) in terms of their effects and side effects. Methods ASD patients that had been initiated to be treated with one of the three antipsychotics that continued for a minimum of eight weeks were included in the study, retrospectively. The participants were recruited with 20 olanzapine using patients (2.5?10 mg/day) in comparison with 42 risperidone (1?4 mg/day) and 40 aripiprazole (3?15 mg/day) using patients that are using the matched equivalent chlorpromazine doses of the antipsychotics between the same time period. Results All three antipsychotics significantly decreased all of the ABC subscales scores in eight weeks. Sleepiness/sedation, increased duration of sleep, and weight gain were the most common side effects of the three antipsychotics and they were more frequent with olanzapine than with the others (X2 = 26.9, p < 0.0001; X2 = 20.8, p < 0.0001; X2 = 8.4, p = 0.01, respectively). Discussion Our results reveal that risperidone, aripiprazole, and olanzapine are effective in treatment of irritability, hyperactivity, social withdrawal, stereotypy, and inappropriate speech in ASD. But the side effects are more frequent with olanzapine and it should be considered when choosing antipsychotics for ASD. En ligne : https://doi.org/10.1016/j.rasd.2020.101520 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421
in Research in Autism Spectrum Disorders > 72 (April 2020) . - p.101520[article] Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Selma TURAL HESAPCIOGLU, Auteur ; Mehmet Fatih CEYLAN, Auteur ; Meryem KASAK, Auteur ; Cansu P?nar SEN, Auteur . - p.101520.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 72 (April 2020) . - p.101520
Mots-clés : Antipsychotic Aripiprazole Autism Spectrum Disorders Irritability Olanzapine Risperidone Index. décimale : PER Périodiques Résumé : Background The aim of this study is to examine the use of olanzapine, risperidone and aripiprazole in autism spectrum disorders (ASD) in terms of their effects and side effects. Methods ASD patients that had been initiated to be treated with one of the three antipsychotics that continued for a minimum of eight weeks were included in the study, retrospectively. The participants were recruited with 20 olanzapine using patients (2.5?10 mg/day) in comparison with 42 risperidone (1?4 mg/day) and 40 aripiprazole (3?15 mg/day) using patients that are using the matched equivalent chlorpromazine doses of the antipsychotics between the same time period. Results All three antipsychotics significantly decreased all of the ABC subscales scores in eight weeks. Sleepiness/sedation, increased duration of sleep, and weight gain were the most common side effects of the three antipsychotics and they were more frequent with olanzapine than with the others (X2 = 26.9, p < 0.0001; X2 = 20.8, p < 0.0001; X2 = 8.4, p = 0.01, respectively). Discussion Our results reveal that risperidone, aripiprazole, and olanzapine are effective in treatment of irritability, hyperactivity, social withdrawal, stereotypy, and inappropriate speech in ASD. But the side effects are more frequent with olanzapine and it should be considered when choosing antipsychotics for ASD. En ligne : https://doi.org/10.1016/j.rasd.2020.101520 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421 Practitioner Review: The effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder / Tobias ATKIN in Journal of Child Psychology and Psychiatry, 58-8 (August 2017)
[article]
Titre : Practitioner Review: The effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder Type de document : Texte imprimé et/ou numérique Auteurs : Tobias ATKIN, Auteur ; Nicolas NUÑEZ, Auteur ; Gabriella GOBBI, Auteur Article en page(s) : p.865-879 Langues : Anglais (eng) Mots-clés : Psychopharmacology paediatric bipolar disorder depression quetiapine aripiprazole lithium valproate mixed state depressive symptoms Index. décimale : PER Périodiques Résumé : Background The management of depressive and mixed symptoms in children and adolescents with bipolar disorder (BD) remains a matter of debate. The goal of this review is, thus, to systematically examine the impact of atypical antipsychotics (AAPs) and mood stabilisers in the treatment of bipolar depression and/or mixed states. Methods A literature search was conducted for studies assessing the efficacy of pharmacological treatments for bipolar disorder type I, type II and not otherwise specified with a recent depressive, mixed or manic episode (with depressive symptoms) following DSM-IV criteria in children and adolescents as either acute or maintenance treatment. The databases searched were PubMed/Medline, Google Scholar and Tripdatabase, as well as ClinicalTrials.gov. The search was limited to clinical trials, systematic reviews, meta-analyses and open-label trials published in the English language between the years 2000 and 2015. Sixty clinical studies were found assessing the efficacy of mood stabilisers and AAPs in paediatric BD. Fifteen studies were not included in the primary analysis because they did not assess depressive symptomology/include scores on rating scales of depressive symptoms (Online Supplementary Material). Results There is sufficient evidence for a Grade A recommendation of the use of olanzapine plus fluoxetine at reducing depressive symptoms in bipolar depression and of quetiapine at high doses for depressive symptoms occurring during mixed episodes. Importantly, even though monotherapy with aripiprazole, risperidone, valproate and lithium was effective at controlling mania, these drugs were not effective at reducing depressive symptoms (level A evidence for nonrecommendation). Conclusions These results mostly overlap with the approved treatments for bipolar depression in adults. En ligne : http://dx.doi.org/10.1111/jcpp.12735 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=316
in Journal of Child Psychology and Psychiatry > 58-8 (August 2017) . - p.865-879[article] Practitioner Review: The effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder [Texte imprimé et/ou numérique] / Tobias ATKIN, Auteur ; Nicolas NUÑEZ, Auteur ; Gabriella GOBBI, Auteur . - p.865-879.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 58-8 (August 2017) . - p.865-879
Mots-clés : Psychopharmacology paediatric bipolar disorder depression quetiapine aripiprazole lithium valproate mixed state depressive symptoms Index. décimale : PER Périodiques Résumé : Background The management of depressive and mixed symptoms in children and adolescents with bipolar disorder (BD) remains a matter of debate. The goal of this review is, thus, to systematically examine the impact of atypical antipsychotics (AAPs) and mood stabilisers in the treatment of bipolar depression and/or mixed states. Methods A literature search was conducted for studies assessing the efficacy of pharmacological treatments for bipolar disorder type I, type II and not otherwise specified with a recent depressive, mixed or manic episode (with depressive symptoms) following DSM-IV criteria in children and adolescents as either acute or maintenance treatment. The databases searched were PubMed/Medline, Google Scholar and Tripdatabase, as well as ClinicalTrials.gov. The search was limited to clinical trials, systematic reviews, meta-analyses and open-label trials published in the English language between the years 2000 and 2015. Sixty clinical studies were found assessing the efficacy of mood stabilisers and AAPs in paediatric BD. Fifteen studies were not included in the primary analysis because they did not assess depressive symptomology/include scores on rating scales of depressive symptoms (Online Supplementary Material). Results There is sufficient evidence for a Grade A recommendation of the use of olanzapine plus fluoxetine at reducing depressive symptoms in bipolar depression and of quetiapine at high doses for depressive symptoms occurring during mixed episodes. Importantly, even though monotherapy with aripiprazole, risperidone, valproate and lithium was effective at controlling mania, these drugs were not effective at reducing depressive symptoms (level A evidence for nonrecommendation). Conclusions These results mostly overlap with the approved treatments for bipolar depression in adults. En ligne : http://dx.doi.org/10.1111/jcpp.12735 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=316